![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/10/2021 18:42 | Great business but now way overvalued | ![]() phillis | |
15/10/2021 00:33 | Sorry, I'm not one of your clique and have put you on filter for wasting my time. | ![]() piedro | |
08/10/2021 07:49 | Now available, Ergomed PLC Interim Results Webcast 2021 | ![]() piedro | |
05/10/2021 17:05 | ... interesting the bit about Japan but .... no mention of their technical developments | ![]() piedro | |
05/10/2021 12:58 | Edison research is, I think, paid for by the company. So while interesting, year it with caution. | ![]() martinc | |
05/10/2021 10:59 | Edison Investment Research Lim Ergomed (ERGO): US is now the biggest market in the mix 4 October 2021 - US is now the biggest market in the mix - FX headwinds, but strong underlying growth - Margins also ‘masked’ by unfavourable FX rate - Valuation: £751m or 1,536p/share - H121 update: Operational momentum continues °° PrimeVigilance: Expanding to Japan °° CRO: Strong post-pandemic rebound continues | ![]() piedro | |
01/10/2021 15:46 | Keep them coming ... Ergomed@ErgomedPLC EXPLORE - To assess various countries’ regulatory framework suitability based on your individual protocol requirements, check out our new Regulatory Framework Tool. Explore now: | ![]() piedro | |
28/9/2021 11:19 | webcast concluded - business as usual - no surprises - developing and integrating technological platforms | ![]() piedro | |
28/9/2021 11:02 | Excellent results from a quality company. | ![]() blueflame | |
28/9/2021 08:35 | looks good to me. | ![]() robow | |
28/9/2021 07:49 | Superb interims yet again! | ![]() ihatemms | |
24/9/2021 15:34 | Ergomed@ErgomedPLC NEWS: We are delighted to share with both our customers and employees the new Ergomed Clinical Research website. It provides easier access to our solutions and services along with some integrated features and tools to assist in planning clinical trials. | ![]() piedro | |
14/9/2021 15:40 | -------------------- -------------------- | ![]() piedro | |
01/9/2021 15:21 | Yep Ergo going great guns at the moment. Must be one of the best performing stocks in my portfolio and yet advfn and lse forums are amongst the quietest. | ![]() bermudashorts | |
01/9/2021 14:59 | Lovely, new all time high. Hopefully it can hang onto it. | ![]() blueflame | |
28/8/2021 10:43 | Pharmacovigilence in the NHS? </>NICE changes to provide faster, fairer access to new drugs and devices We’re changing how we assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS. ... ... | ![]() piedro | |
27/8/2021 18:15 | I'm not a holder unfortunately but I do take a keen interest in its progress and it doesn't take a market wizard to see that's someone's upping their interest for as of yet reasons unknown | ![]() mirabeau | |
27/8/2021 16:10 | Hmmm is something else going on... | ![]() blueflame | |
27/8/2021 14:26 | Fingers crossed:-) | ![]() blueflame | |
27/8/2021 13:02 | This is breaking out | ![]() mirabeau | |
20/8/2021 12:19 | Hope they are not more sales by the directors like the other day. What I find frustrating is that the 1.2m offloaded didn't show up on the trades pages. The trade data is absolutely pointless but fools pi's into thinking that there are more buys than sells. | ![]() blueflame | |
20/8/2021 10:36 | x 2 chunky trades today | ![]() mfhmfh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions